Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Inclusion Criteria: * Patients with mild to moderate essential hypertension (Grade I and Grade II) with mean sitting office SBP =140-179 mmHg and/or mean sitting office DBP = 90 -109 mmHg on 2 consecutive visits (screening and V1). * Daytime blood pressure above threshold for definition of hypertension in the baseline ABPM measurement (SBP \>135 mmHg). * Stable baseline blood pressure confirmed on 2 consecutive visits (screening and V1). (Changes \<20mmHg for sitting office SBP and \<10mmHg for mean sitting office DPB). * Patients without current antihypertensive therapy. Patients on previous mono-antihypertensive therapy, who can safely stop their medication * Patient is willing and able to comply with all trial requirements and procedures. Exclusion Criteria: * Patients with "very high added risk" according to 2007 Guidelines for the Management of Arterial Hypertension (Journal of Hypertension, 2007, 25:1105- 1187), i.e. those with:grade III hypertension (mean sitting office SBP * 180mmHg and/or meansitting DBP ≥110mmHg/history or presence of established cardiovascular or renal disease (Ischemic stroke, cerebral hemorrhage, transient ischemic attack)/ Myocardial infarction, angina pectoris, coronary re-vascularization/ clinically relevant heart failure (NYHA class II-IV)/ Peripheral artery disease/ Diabetic nephropathy * Electrocardiographic confirmed left ventricular hypertrophy * Increased plasma creatinine * Diabetes mellitus type I, history, presence or new diagnosis of diabetes mellitus type II. * Postural hypotension at screening * Arrhythmias that would interfere with the oscilloscopic measurement of the blood pressure. * Known autoimmune disease. * Severe allergy. * Pregnancy or breastfeeding. * Women in childbearing age that are not surgically sterilized. * Patients with a history or current positive test for HIV infection, AIDS, or other immunosuppressive disorders; hepatitis B or C. * Current diagnosis or history of malignancy.